TAKASAGO INTERNATIONAL CORPORATION
4914・Prime Market・Chemicals
Business
Takasago International Corporation, founded in 1920, is Japan's leading domestic flavors and fragrances company, operating four business segments: Flavors (flavors for food applications), Fragrances (perfumery materials), Aroma Ingredients (fragrance materials such as menthol), and Fine Chemicals (pharmaceutical intermediates, catalysts, etc.). In addition to Japan, the company operates on a four-region basis spanning the Americas, Europe, and Asia, with 42 consolidated subsidiaries and 1 affiliated company. Net sales for FY2026 (ending March 2026) were ¥225,092 million, with the overseas sales ratio reaching 66%. Major customers span a broad range of consumer goods companies, including food and beverage, daily necessities, and pharmaceutical manufacturers, to whom the company supplies a wide variety of fragrance and flavor materials in small quantities on a global scale.
Business Model
By leveraging core technologies such as proprietary asymmetric synthesis and catalytic reactions, the company organically integrates its four business segments—Flavors, Fragrances, Aroma Ingredients, and Fine Chemicals—to generate unique synergies not available to competitors. It secures stable revenue by proposing scent creation and formulations tailored to customers' product development needs and continuously supplying a wide variety of fragrance products in small quantities. The company invests ¥17,494 million annually (FY2026, ending March 2026) in R&D expenses to maintain and strengthen its technological advantage.
Company Strengths
The company has manufacturing, research, and sales bases across the four regions of Japan, Americas, Europe, and Asia, achieving overseas sales of ¥148,124 million and an overseas sales ratio of 66% in FY2026 (ending March 2026). The Asia segment recorded operating profit of ¥5,650 million, making it the Group's largest profit-contributing segment, and the company has achieved both global customer responsiveness and earnings stability through regional diversification.
Based on proprietary technologies such as catalytic asymmetric synthesis and continuous flow reactions, the company has developed synergies across four business segments by horizontally deploying technologies cultivated in Aroma Ingredients manufacturing into Fine Chemicals (pharmaceutical intermediates) and flavor/fragrance compounding. In-house developed ligands and catalysts such as BINAP and SEGPHOS® are used internally as well as sold externally, realizing the commercialization of technology.
Total R&D expenses for FY2026 (ending March 2026) amounted to ¥17,494 million (Japan: ¥6,226 million, overseas: ¥11,267 million). In July 2022, the Molecular Transformation Research Institute and the Bio Design Research Institute were newly established, forming an eight-institute research structure. A total of 1,019 research staff in Japan and overseas (320 in Japan, 697 overseas, and 2 at domestic subsidiaries) collaborate to promote three types of innovation: concept, product, and process innovation.
ENVALITH's Perspective
Performance Trend
Revenue continued its expansionary trend from ¥162,440 million in FY2022 (ended March 2022) to ¥229,207 million in FY2025 (ended March 2025), but turned slightly downward in FY2026 (ending March 2026) to ¥225,092 million (down 1.8% year on year). Operating profit staged a V-shaped recovery from a trough of ¥2,316 million in FY2024 (ended March 2024) to ¥15,341 million in FY2025 (ended March 2025), but then plunged in FY2026 (ending March 2026) to ¥8,132 million (down 47.0% year on year). The main causes were a postponement of pharmaceutical intermediate shipments in the Fine Chemicals segment due to the upgrading of its quality control system (resulting in an operating loss of ¥827 million in that segment) and the cost of introducing a new core system at the French subsidiary. On the other hand, the Asia segment remained solid with operating profit of ¥5,650 million (up 14.2% year on year). Operating cash flow declined substantially from ¥18,922 million to ¥4,271 million, and aggressive investment of ¥19,261 million in acquisition of property, plant and equipment caused the cash balance to decrease from ¥35,585 million to ¥19,572 million. The equity ratio stood at 56.6%, maintaining sound financial health.
Growth Strategy
Targeting earnings recovery in FY2027 (ending March 2027) based on NGP-2's three pillars: overseas growth, improvement of domestic profitability, and sustainable management
By completing upgrades to the quality control system in response to requirements from key customers and resuming shipments of overseas pharmaceutical intermediates, the company aims to normalize earnings in this segment, which recorded an operating loss of ¥827 million in FY2026 (ending March 2026). This is one of the key assumptions underlying the earnings recovery forecast for FY2027 (ending March 2027).
Shipment adjustments and increased depreciation expenses associated with the introduction of the new core system pushed down operating profit in the Europe segment by 67.4% year on year. The company aims to recover profitability in the Europe segment through normalization of shipments and a gradual reduction in cost burden following stabilization of the new system's operations.
The company continues to improve gross profit through increased shipments of beverage Flavors and fabric care Fragrances at its Chinese subsidiary, together with raw material optimization. It aims to capture growth opportunities in the Southeast Asian market and strengthen its position as the group's largest profit-contributing segment.
In FY2026 (ending March 2026), the company made acquisitions of tangible fixed assets of ¥19,261 million (up 70.4% year on year), including a ¥10,365 million increase in land acquisitions, substantially expanding its fixed asset base. Through medium-term expansion of production capacity and strengthening of quality infrastructure, the company aims to enhance its global competitiveness.
In response to rising raw material procurement costs driven by higher crude oil prices and logistics disruptions amid instability in the Middle East, the company has revised selling prices and optimized raw material procurement. In the Aroma Ingredients segment, operating profit declined 20.9% year on year due to rising raw material prices, and minimizing this impact remains a key challenge.
Last updated: July 19, 2026